Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Annovis Bio Inc. | Buntanetap | Parkinson's Disease (PD) | Phase 3 | Ongoing | Oral | Neurology |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) subcutaneous | Complement-dependent Nephropathies (CDN) | Phase 2 | Trial Discontinued | Subcutaneous | Immunology |
| Apellis Pharmaceuticals Inc. | APL-3007 | Small interfering RNA silencing C3 | Phase 2 | Trial Planned | Oral | Genetic Disorder |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) - (OAKS) | Geographic atrophy (GA) associated with age-related macular degeneration (AMD) | Phase 3 | Trial Completed | Subcutaneous | Opthalmic |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) subcutaneous | Complement-dependent Nephropathies (CDN) | Phase 2 | Trial Discontinued | Subcutaneous | Immunology |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) - (MERIDIAN) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Trial Discontinued | Subcutaneous | Neurology |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) subcutaneous | Cold agglutinin disease (CAD) | Phase 3 | Trial Completed | Subcutaneous | Hematology |
| Apellis Pharmaceuticals Inc. | EMPAVELI (pegcetacoplan) - (MERIDIAN) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Trial Discontinued | Subcutaneous | Neurology |
